PICCIN, Daniela
 Distribuzione geografica
Continente #
NA - Nord America 1462
EU - Europa 452
AS - Asia 239
Totale 2153
Nazione #
US - Stati Uniti d'America 1459
CN - Cina 181
DE - Germania 140
UA - Ucraina 119
GB - Regno Unito 55
TR - Turchia 52
SE - Svezia 30
IT - Italia 28
FI - Finlandia 27
BE - Belgio 19
RU - Federazione Russa 19
FR - Francia 9
CA - Canada 3
IE - Irlanda 2
IN - India 2
IR - Iran 2
NL - Olanda 2
BD - Bangladesh 1
CZ - Repubblica Ceca 1
KZ - Kazakistan 1
RO - Romania 1
Totale 2153
Città #
Woodbridge 277
Fairfield 164
Jacksonville 139
Chandler 131
Houston 129
Ann Arbor 99
Seattle 69
Wilmington 60
Ashburn 55
Beijing 54
Cambridge 54
Addison 47
Izmir 44
Nanjing 38
Princeton 27
Milan 23
Boardman 21
San Diego 21
Brussels 19
Dearborn 16
Shenyang 15
Kunming 11
Guangzhou 8
Hebei 8
Jiaxing 8
Nanchang 8
Jinan 7
Changsha 6
Norwalk 6
San Mateo 6
Leawood 5
Mountain View 5
Redwood City 5
Des Moines 4
Falls Church 4
Tianjin 4
Washington 4
Hangzhou 3
Monmouth Junction 3
Montréal 3
Munich 3
Ardabil 2
Augusta 2
Dublin 2
Hefei 2
Helsinki 2
New York 2
Philadelphia 2
Taizhou 2
Verona 2
Almaty 1
Bremen 1
Changchun 1
Delhi 1
Dhaka 1
Ferrara 1
Hanover 1
Jinhua 1
Mcallen 1
Messina 1
Mumbai 1
Ningbo 1
Paris 1
Shanghai 1
Yellow Springs 1
Zhengzhou 1
Totale 1647
Nome #
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 136
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 129
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 129
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 128
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 106
null 106
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 102
miR-15a and miR-16-1 down-regulation in pituitary adenomas 98
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. 97
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 96
Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. 95
An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro 90
Role of complex Cdk4/Cyclin D1 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro 78
Antiproliferative effects of somatostatin analogs in pituitary adenomas 77
Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. 77
SHP-1 restrains cell proliferation in human medullary thyroid carcinoma 76
Multiple somatostatin receptor subtypes activation reduces cell viability in non-functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion 71
Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin A secretion and on cell viability in human non-functioning pituitary adenomas in vitro 64
Selective Cyclo-oxygenase 2 inhibitors revert chemoresistance In Medullary thyroid carcinoma by a mechanism mediated by P-gp and PGH2 61
Chemoresistance of Medullary thryroid carcinoma cells is reversed by COX-2 inhibitors in vitro through a PGE2-dependent mechanism 59
Role of complex Cyclin D1/Cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro. 58
Somatostatin inhibits a medullary thyroid carcinoma cell line growth by activating SHP-1 58
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone (GHRH)-secreting bronchial carcinoid 58
SSTR subtypes expression pattern influences the antiproliferative effects of somatostatin and lanreotide on human medullary thyroid carinomas in vitro 53
Somatostatin differentially influences proliferation and gene expression by modulating SHP-1 and cAMP pathways in a human medullary thyroid carcinoma cell line 53
Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro 11
Totale 2166
Categoria #
all - tutte 4621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4621


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019348 661014 151 426 274760114
2019/2020510 76162061 4261 4354 3754397
2020/2021287 3429833 1229 1132 6344910
2021/2022330 1041316 1812 1711 102133120
2022/2023288 28242435 3646 2817 334130
Totale 2166